Criticism of MADIT Trial: Beta blocker use was more in the ICD arm than conventional therapy arm, which could have contributed to better results in the ICD.
Bivalirudin is a synthetic 20 amino acid polypeptide. It interacts bivalently with both active catalytic site and exosite 1 of thrombin. Bivalirudin inactivates both free and fibrin bound thrombin.
CHADS2 score was developed to assess the risk of thromboembolism in non valvar atrial fibrillation. Scores were allotted to various risk factors as follows:
Congestive heart failure: 1
History of